Cargando…
Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants
BACKGROUND: Target antigen (Ag) loss has emerged as a major cause of relapse after chimeric antigen receptor T (CART)-cell therapy. We reasoned that the combination of CART cells, with the consequent tumor debulking and release of Ags, together with an immunomodulatory agent, such as the stimulator...
Autores principales: | Conde, Enrique, Vercher, Enric, Soria-Castellano, Marta, Suarez-Olmos, Jesús, Mancheño, Uxua, Elizalde, Edurne, Rodriguez, M Luis, Glez-Vaz, Javier, Casares, Noelia, Rodríguez-García, Estefanía, Hommel, Mirja, González-Aseguinolaza, Gloria, Uranga-Murillo, Iratxe, Pardo, Julian, Alkorta, Gorka, Melero, Ignacio, Lasarte, Juan, Hervas-Stubbs, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609946/ https://www.ncbi.nlm.nih.gov/pubmed/34810235 http://dx.doi.org/10.1136/jitc-2021-003351 |
Ejemplares similares
-
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
por: Martín-Otal, Celia, et al.
Publicado: (2022) -
Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes
por: Arranz-Nicolás, Javier, et al.
Publicado: (2020) -
Biomarkers of tumor-reactive CD4(+) and CD8(+) TILs associate with improved prognosis in endometrial cancer.
por: Palomero, Jara, et al.
Publicado: (2022) -
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
por: Moreno-Castaño, Ana Belen, et al.
Publicado: (2023) -
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)